An interventional study of Patient-Reported Outcomes Dashboard With Goal Setting in Arthritis, Psoriatic (PsA) and Arthritis, Rheumatoid (RA), sponsored by Northwestern University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Northwestern University · Not applicable, Interventional, and Health services research
The goal of this clinical trial is to learn whether showing patient-reported symptoms and personal treatment goals to rheumatology clinicians on a dashboard in the electronic health record improves shared decision-making for adults with rheumatoid arthritis or psoriatic arthritis.
The main questions it aims to answer are:
Researchers will compare the dashboard group to a usual care group to see if the dashboard improves shared decision-making, goal attainment, and self-efficacy.
Participants will:
Participants in the dashboard group will also complete questionnaires in the patient portal about pain, fatigue, physical function, sleep, and morning stiffness before each visit. Their answers and goals will be shown to their clinician on a dashboard to guide the conversation during the visit.
579 studies on the registry are indexed under Arthritis, Psoriatic; 132 are open to participants now.
This study's planned enrollment of 160 is above the median of 135 across 322 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Northwestern University is the lead sponsor of 1,398 studies on the registry; 201 are open to participants now.
Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Before each of two routine rheumatology visits approximately 6 months apart, participants complete the RAPID3 (standard of care for all clinic patients) plus an additional questionnaire series in the patient portal: selection of personal treatment goals, a morning stiffness question, and four PROMIS computer adaptive tests (Pain Interference, Fatigue, Physical Function, and Sleep Disturbance). Responses and goals are displayed to the treating clinician on a dashboard in the electronic health record for use during the visit.
Other: Patient-Reported Outcomes Dashboard With Goal Setting
Participants receive usual rheumatology care. They do not receive the additional questionnaire series, and no study dashboard is displayed to the clinician. For outcome assessment only, participants select personal goals and rate goal attainment in study surveys that are not shared with the clinician.
A clinician-facing dashboard embedded in the Epic electronic health record that displays the participant's PROMIS computer adaptive test (CAT) scores (PROMIS Pain Interference, PROMIS Fatigue, PROMIS Physical Function, PROMIS Sleep Disturbance), morning stiffness, and self-selected treatment goals collected through the patient portal before the visit. Clinicians receive training on using the dashboard to support shared decision-making and goal-directed care during the visit.
Shared Decision-Making
CollaboRATE is a 3-item patient-reported measure of shared decision-making during a clinical encounter. Each item is rated from 0 (no effort was made) to 9 (every effort was made). The score is the mean of the three items (range 0 to 9); higher scores indicate more shared decision-making.
Time frame: Within 48 hours after the second study visit (approximately 6 months after enrollment)
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwestern University